Prospect of CAR T-cell therapy in acute myeloid leukemia.
Talha BadarAlak MannaMartha E GaddMohamed A Kharfan-DabajaHong QinPublished in: Expert opinion on investigational drugs (2022)
CAR T-cell therapy has shown promise as a novel therapy, but there are number of barriers to overcome to achieve its full therapeutic potential in AML. Targeting leukemia-specific antigen such as CLL1, to avoid myelotoxicity, incorporating checkpoint inhibitors to overcome leukemia-induced immunosuppression and allogenic CAR T cells to increase accessibility to patients with proliferative disease are among the strategies that are being explored to make CAR T cell a successful immunotherapy for patient with AML.
Keyphrases
- cell therapy
- acute myeloid leukemia
- stem cells
- allogeneic hematopoietic stem cell transplantation
- mesenchymal stem cells
- high glucose
- bone marrow
- dna damage
- diabetic rats
- case report
- cell cycle
- cancer therapy
- drug induced
- endothelial cells
- cell proliferation
- oxidative stress
- drug delivery
- stress induced
- replacement therapy